NeuroOne Medical Technologies (NASDAQ:NMTC) reported an insider transaction on March 1, 2026, with Chief Business Officer David J. Wambeke acquiring 1,000,000 shares of the companys common stock at a per-share price of $0.6704. The total value of the equity purchase was $670,400.
In addition to the share purchase, Wambeke obtained 500,000 options to buy common stock at an exercise price of $0.6704. Those options carry a maturity date of February 29, 2036, and they vest in installments beginning on March 1, 2027.
The insider buy comes in the context of a challenging year for the stock. NeuroOne shares have declined 38% over the past 12 months and are trading near a reported 52-week low of $0.40.
On the corporate performance front, NeuroOne posted Q1 Fiscal 2026 results that slightly outperformed Street expectations. The company recorded a net loss of $1.4 million, or $0.03 per share, compared with anticipated earnings per share of negative $0.04. Revenue for the quarter was $2.9 million, narrowly above the forecast of $2.86 million.
Despite those results beating estimates on both the bottom line and revenue, NeuroOne stock declined in premarket trading following the release.
Analyst coverage and valuation viewpoints cited alongside the insider filing note a range of price targets: analysts set targets from $1.50 to $3.00. An analysis from InvestingPro referenced in filings indicates NMTC appears undervalued at current levels and notes the company holds more cash than debt on its balance sheet. The InvestingPro commentary also states that subscribers have access to five additional key tips about the companys financial health.
Separately, Jones Trading has initiated coverage on NeuroOne with a Buy rating and assigned a $1.50 price target. Jones Trading highlighted the companys product revenue growth, which it reported rose from $3.5 million in fiscal year 2024 to $9.1 million in fiscal year 2025, attributing that increase to sales of the OneRF Ablation System.
Taken together, the insider purchase and the recent earnings report provide concrete data points on NeuroOnes recent operational and market activity. The options award structure and vesting timeline are explicit in the filing, and the companys recent financial performance is captured in the quarter results and the revenue progression noted by Jones Trading.
Clear summary
NeuroOne CBO David J. Wambeke bought 1,000,000 shares at $0.6704 each on March 1, 2026, and received 500,000 long-dated options at the same exercise price expiring February 29, 2036, with vesting starting March 1, 2027. The company reported a Q1 Fiscal 2026 net loss of $1.4 million, or $0.03 per share, and revenue of $2.9 million, both slightly ahead of estimates. Analysts coverage shows price targets between $1.50 and $3.00, while Jones Trading started coverage with a Buy and $1.50 target.
Key points
- Insider transaction: 1,000,000 shares purchased at $0.6704 per share on March 1, 2026, totaling $670,400.
- Options granted: 500,000 options exercisable at $0.6704, expiring February 29, 2036, vesting beginning March 1, 2027.
- Recent financials: Q1 Fiscal 2026 net loss of $1.4 million (-$0.03 per share) and revenue of $2.9 million, both modestly beating expectations.
Risks and uncertainties
- Share price weakness - The stock has fallen 38% over the past year and is trading near a 52-week low of $0.40, reflecting market volatility in small-cap medical device names.
- Dependence on product growth - Jones Trading highlighted product revenue growth driven by the OneRF Ablation System; future results could be sensitive to adoption of that product.
- Limited visibility from current filings - While InvestingPro notes the company holds more cash than debt and offers subscribers additional tips, that level of detail may not be fully accessible to all investors.